8-K: Forte Biosciences Reports Q3 2025, Eyes 3 Key FB102 Readouts in 2026

Forte Biosciences announced its third quarter 2025 financial results and provided an update on its FB102 clinical programs, with three key trial readouts anticipated in 2026.

Summary

• Research and development expenses were $15.2 million for the three months ended September 30, 2025, a significant increase from $5.9 million for the same period in 2024.
• For the nine months ended September 30, 2025, research and development expenses totaled $36.5 million, up from $16.0 million in the prior year period.
• General and administrative expenses were $3.2 million for Q3 2025, compared to $2.8 million for Q3 2024.
• General and administrative expenses for the nine months ended September 30, 2025, decreased to $9.6 million from $13.3 million in the same period of 2024.
• Net loss per share improved to $(0.99) for Q3 2025, compared to $(4.54) for Q3 2024.
• Net loss per share for the nine months ended September 30, 2025, improved to $(3.26), compared to $(15.35) for the same period in 2024.
• Forte Biosciences ended the third quarter of 2025 with $93.4 million in cash and cash equivalents.
• The US IND for FB102 is now open, and enrollment in the FB102 Phase 2 celiac disease clinical trial has expanded to US sites, with topline results expected in 2026.
• The FB102 Phase 1b vitiligo clinical study is ongoing, with topline data expected in the first half of 2026.
• Enrollment has begun for the FB102 Phase 1b trial in alopecia areata, with data expected in 2026.

Sentiment

Score: 7

Explanation: The company reported significant progress in its clinical programs for FB102, including expanding trials to the US and anticipating three key data readouts in 2026, which are positive catalysts. The cash position is strong, and net loss per share has improved. However, R&D expenses have substantially increased due to trial advancements, reflecting the high cost of drug development.

Positives

• The US IND for FB102 is open, allowing the expansion of the Phase 2 celiac disease trial to US sites.
• Enrollment has commenced for the Phase 1b trial in alopecia areata, adding another indication to the clinical pipeline.
• Positive results from the FB102 Phase 1b celiac disease trial were reported in June, providing a strong foundation for the ongoing Phase 2 study.
• The company ended Q3 2025 with a robust cash and cash equivalents balance of $93.4 million, a significant increase from $22.244 million at December 31, 2024.
• Net loss per share significantly improved to $(0.99) in Q3 2025 from $(4.54) in Q3 2024, and to $(3.26) for the nine months ended September 30, 2025, from $(15.35) in the prior year period.
• General and administrative expenses decreased for the nine months ended September 30, 2025, to $9.6 million from $13.3 million in the same period of 2024, primarily due to lower professional and legal expenses.

Negatives

• Research and development expenses increased substantially to $15.2 million for Q3 2025 from $5.9 million for Q3 2024, and to $36.5 million for the nine months ended September 30, 2025, from $16.0 million for the same period in 2024, driven by increased clinical and manufacturing costs.
• The company continues to report net losses, with a net loss of $(17.682) million for Q3 2025 and $(44.587) million for the nine months ended September 30, 2025.

Risks

• Risks related to Forte's ability to obtain sufficient additional capital to continue to advance its product candidate, FB102.
• Uncertainties associated with the clinical development and regulatory approval of FB102, including potential delays in the commencement, enrollment, and completion of clinical trials.
• The risk that results from preclinical and any interim results of ongoing clinical trials may not be predictive of future results from clinical trials.
• Risks associated with the failure to realize any value from FB102 due to inherent risks, expense, and difficulties involved in successfully bringing product candidates to market.

Future Outlook

Forte Biosciences anticipates a very eventful 2026 with three key clinical trial readouts for its FB102 program, including Phase 2 data for celiac disease, and Phase 1b data for both vitiligo and alopecia areata. These readouts are expected to further highlight FB102's potential to address significant unmet medical needs across multiple multi-billion dollar market opportunities.

Management Comments

• "We continue to make excellent progress with FB102."
• "The US IND is now open and enrolment in the FB102 phase 2 celiac disease (CeD) clinical trial has expanded to US sites with topline results expected in 2026."
• "Based on the strength of the positive results from the FB102 phase 1b CeD trial, which we reported in June, we look forward to the phase 2 data further validating FB102 for the treatment of celiac disease."
• "With 3 key clinical trial readouts for FB102, 2026 will be a very eventful year and further highlight FB102s potential to address the significant unmet medical needs across multiple indications including celiac disease, vitiligo and alopecia areata, which represent multi-billion dollar potential market opportunities."

Industry Context

Forte Biosciences is a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, a significant and growing market. Its lead candidate, FB102, an anti-CD122 monoclonal antibody, targets celiac disease, vitiligo, and alopecia areata, which are conditions with substantial unmet medical needs and multi-billion dollar market potential. The expansion of trials to US sites and multiple upcoming data readouts position the company to potentially capture market share in these therapeutic areas, aligning with broader industry trends of developing targeted therapies for autoimmune conditions.

Stakeholder Impact

• Shareholders: Potential for increased value if clinical trials are successful, but also risk of dilution if additional capital is raised. Improved net loss per share is positive.
• Employees: Increased headcount mentioned in R&D and G&A suggests growth and stability.
• Patients: Potential for new therapeutic options for celiac disease, vitiligo, and alopecia areata if FB102 proves safe and effective.
• Creditors: Strong cash position ($93.4 million) indicates good short-term liquidity.

Next Steps

• Continue enrollment in the FB102 Phase 2 celiac disease clinical trial, including US sites.
• Continue the FB102 Phase 1b vitiligo clinical study.
• Continue enrolling patients in the FB102 Phase 1b trial in alopecia areata.
• Anticipate topline data from the FB102 Phase 1b vitiligo clinical study in 1H 2026.
• Anticipate topline data from the FB102 Phase 2 celiac disease clinical trial in 2026.
• Anticipate data from the FB102 Phase 1b alopecia areata trial in 2026.
• Pursue additional autoimmune indications for FB102.

Key Dates

Recommendation

Forte Biosciences shows promising clinical progress with its lead candidate FB102, expanding trials and anticipating three key data readouts in 2026 for significant autoimmune indications. The company also maintains a strong cash position of $93.4 million and has shown an improvement in net loss per share. However, the substantial increase in R&D expenses reflects the high burn rate typical of clinical-stage biotechs, and future capital raises are explicitly noted as a risk. Given the early-to-mid-stage nature of the trials and the inherent risks of drug development, a "hold" recommendation is appropriate. Investors should await the upcoming clinical data readouts in 2026 for further validation of FB102's potential before making more aggressive investment decisions.

Keywords

Forte Biosciences, FB102, celiac disease, vitiligo, alopecia areata, autoimmune diseases, clinical trials, biopharmaceutical, Q3 2025 results, R&D expenses, cash position, NASDAQ: FBRX